Ad
related to: her2 survival rate with herceptin- Prescribing Information
Download Prescribing Information
Additional Resources For Physicians
- Request More Information
Be The First To Get Updates
And News About TUKYSA®
- Safety Information
Access Clinical Safety Info
Keep Current On News For Physicians
- Download Resources
For Healthcare Professionals
About A Treatment Option
- Prescribing Information
Search results
Results from the WOW.Com Content Network
Trastuzumab has had a "major impact in the treatment of HER2-positive metastatic breast cancer." [40] The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone. [41]
HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy. [33] Twelve months of trastuzumab therapy is optimal.
In trials conducted with a combination of anti-HER2 agents and an aromatase inhibitor, significant clinical benefit and improved progression-free survival have been observed. [22] Trastuzumab is an example of an anti-HER2 agent which mainly depresses the growth of cells which are over-expressing HER2. [23]
When a tumor is “triple positive,” that means that its growth is fueled by both estrogen and progesterone hormones, as well as a protein called human epidermal growth factor receptor 2 (HER2).
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Since 9 of the 17 HER2/neu-positive individuals in this study received a HER2/Neu-targeting drug, trastuzumab ... Ten year disease-free survival rates were about 50% ...
Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...
Trastuzumab, a monoclonal antibody against HER2, added to chemotherapy, has been proven in clinical trials to extend the time to disease progression, increase response rates, prolong response duration, reduce the death rate at 1 year, improve overall survival, and lower the risk of death by 20%. This demonstrates trastuzumab's significant ...
Ad
related to: her2 survival rate with herceptin